Aron R. English Acquires 10,101,010 Shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Stock

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Aron R. English purchased 10,101,010 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the acquisition, the director now owns 15,467,300 shares in the company, valued at $15,312,627. This trade represents a 188.23 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Anebulo Pharmaceuticals Stock Performance

Shares of Anebulo Pharmaceuticals stock opened at $1.70 on Friday. Anebulo Pharmaceuticals, Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $3.30. The company has a market cap of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09. The firm has a 50-day simple moving average of $1.57 and a two-hundred day simple moving average of $1.93.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. Equities research analysts forecast that Anebulo Pharmaceuticals, Inc. will post -0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Benchmark reiterated a “speculative buy” rating and set a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.